浙江医药：注射用重组人源化抗CD70单抗-AS269偶联物获得药物临床试验批准通知书

array(1) { [411840]=> array(2) { [2]=> array(4) { [0]=> string(12) "并购重组" [1]=> string(12) "临床试验" [2]=> string(12) "浙江医药" [3]=> string(18) "核准资产重组" } [4]=> array(1) { [0]=> string(19) "同花顺7x24快讯" } } }